Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23089858 | 0.91 | CA1 (0.49) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL23089857 | 0.91 | CA1 (0.49) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL29728278 | 0.90 | MEN1 (0.45) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL16229379 | 0.90 | MEN1 (0.45) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL30885971 | 0.85 | MEN1 (0.49) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL7275053 | 0.85 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL31026308 | 0.84 | MEN1 (0.41) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL14015716 | 0.83 | MEN1 (0.45) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL14155384 | 0.83 | MEN1 (0.45) | MEN1GAAKMT2ATDP1CA12 | |
| SCHEMBL1262055 | 0.83 | CA12 (0.46) | MEN1GAAKMT2ATDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226892-A1 | HYDRAZONE 3H-IMIDAZO(4,5-B)PYRIDINE COMPOUNDS AND USES THEREOF | Verge Analytics, Inc. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-3426248-B1 | BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4041229-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-108778273-B | Bicyclic aryl monocyclic beta-lactam compounds and methods of use thereof for treating bacterial infections | 默沙东公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2006136460-A2 | NEW ADJUVANT | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6991775-B2 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
| EP-1420681-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | Epix Medical, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | Factor 1A, LLC | 2003-11-20 | — | — | US | disclosed |
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003011115-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | EPIX MEDICAL, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | MEN1 41/4885GAA 2063/4885KMT2A 4290/4885 |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | MEN1 1151/4885GAA 2669/4885KMT2A 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.